Home › Entities › clinical_trial › Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

clinical trial
MedicalStudy clinical_trial Q63570832
Press Enter · cited answer in seconds

Summary

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis is a clinical trial[1].

Key Facts

  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis is in the country of United States[2].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's instance of is recorded as clinical trial[3].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's start time is recorded as +2017-12-14T00:00:00Z[4].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's end time is recorded as +2020-10-31T00:00:00Z[5].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's sponsor is recorded as Memorial Sloan Kettering Cancer Center[6].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's main subject is recorded as amyloidosis[7].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's main subject is recorded as multiple myeloma[8].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's number of participants is recorded as {'unit': '1', 'amount': '+28'}[9].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's title is recorded as Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis[10].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+60'}[11].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's ClinicalTrials.gov ID is recorded as NCT03315026[12].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}[13].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's research intervention is recorded as siltuximab[14].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's clinical trial phase is recorded as phase II clinical trial[15].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's research site is recorded as Memorial Sloan Kettering Cancer Center[16].
  • Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis's study type is recorded as interventional study[17].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.
  16. [17] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis. Retrieved May 3, 2026, from https://4ort.xyz/entity/siltuximab-to-decrease-symptom-burden-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma-and-al-amyloidosis
MLA “Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/siltuximab-to-decrease-symptom-burden-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma-and-al-amyloidosis.
BibTeX @misc{4ortxyz_siltuximab-to-decrease-symptom-burden-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma-and-al-amyloidosis_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis}}, year = {2026}, url = {https://4ort.xyz/entity/siltuximab-to-decrease-symptom-burden-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma-and-al-amyloidosis}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis — https://4ort.xyz/entity/siltuximab-to-decrease-symptom-burden-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma-and-al-amyloidosis (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/siltuximab-to-decrease-symptom-burden-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma-and-al-amyloidosis · Last refreshed: